Levothyroxine (Synthroid ® )
|The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.|
Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate]
| [Prescribed dose] [5 ml] [Infuse immediately after reconstitution]
DO NOT ADD TO OTHER IV FLUIDS.
Stability / Miscellaneous
| Mix on floor just prior to administration. Normally given IV-push.
INDICATIONS AND USAGE
DOSAGE AND ADMINISTRATION
A daily maintenance dose of 50 to 100 mcg parenterally should suffice to maintain the euthyroid state, once established. Close observation of the patient, with individual adjustment of the dosage as needed, is recommended. In infants and children, there is great urgency to achieve full thyroid replacement because of the critical importance of thyroid hormone in sustaining growth and maturation. Despite the smaller body size, the dosage needed to sustain a full rate of growth, development and general thriving is higher in the child than in the adult.
Optimal maintenance levels should be adjusted individually to obtain normal serum T3, T4, free T4, index and Thyroid Stimulating Hormone (TSH) values after several weeks of therapy for hypothyroidism. The patent’s clinical status is most important and some patents may be clinically euthyroid with individual laboratory values that are not within normal range (i.e., elevated total T4 with normal T3). An exception may be seen in congenital hypothyroidism where elevated serum TSH values may persist for the first two to three years of life despite normalization of free T4 measurements. In such cases, it generally is recommended that maintenance of normal serum free T4 values alone should be considered therapeutically sufficient.
In myxedema coma or stupor, without concomitant severe heart disease, 200 to 500 mcg of Levothyroxine Sodium for Injection may be administered IV as a solution containing 100 mcg/mL. DO NOT ADD TO OTHER IV FLUIDS. Although the patient may show evidence of increased responsivity within six to eight hours, full therapeutic effect may not be evident until the following day. An additional 100 to 300 mcg or more may be given on the second day if evidence of significant and progressive improvements has not occurred. Levothyroxine Sodium for Injection produces a predictable increase in the reservoir level of hormone with a seven day half-life. This usually precludes the need for multiple injections but continued daily administration of lesser amounts parenterally should be maintained until the patient is fully capable of accepting a daily oral dose.
In the presence of concomitant heart disease, the sudden administration of such large doses of Lthyroxine IV is clearly not without its cardiovascular risks. Under such circumstances, IV therapy should not be undertaken without weighing the alternative risks of the myxedema coma and the cardiovascular disease. clinical judgment in this situation may dictate smaller IV doses of Levothyroxine Sodium for Injection.
The age and general physical condition of the patient and the severity and duration of hypothyroid symptoms determine the starting dosage and the rate of incremental dosage increase leading to a final maintenance dosage. Clearly it is the physician’s judgment of the severity of the disease and closer observation of patient response which determine the rate and extent of dosage increase. Appropriate laboratory tests are beneficial in monitoring thyroid replacement therapy. Although measurements of normal blood levels of thyroxine in patients on oral replacement regimens frequently coincide with clinical impressions of normal thyroid status, higher than normal levels occur occasionally and should not be considered evidence of overdosage per se. In all cases, clinical impressions of the well being of the patient take precedence over laboratory determination of appropriate individual dosage.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Source: [package insert]
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user’s use of or reliance upon this material.PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read the disclaimer